KR102770671B1 - 항-Pre-S1 HBV 항체 - Google Patents

항-Pre-S1 HBV 항체 Download PDF

Info

Publication number
KR102770671B1
KR102770671B1 KR1020177036711A KR20177036711A KR102770671B1 KR 102770671 B1 KR102770671 B1 KR 102770671B1 KR 1020177036711 A KR1020177036711 A KR 1020177036711A KR 20177036711 A KR20177036711 A KR 20177036711A KR 102770671 B1 KR102770671 B1 KR 102770671B1
Authority
KR
South Korea
Prior art keywords
ser
seq
chain variable
variable region
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177036711A
Other languages
English (en)
Korean (ko)
Other versions
KR20180009780A (ko
Inventor
지안화 수이
단 리
웬후이 리
Original Assignee
화후이 헬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화후이 헬스 리미티드 filed Critical 화후이 헬스 리미티드
Publication of KR20180009780A publication Critical patent/KR20180009780A/ko
Application granted granted Critical
Publication of KR102770671B1 publication Critical patent/KR102770671B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020177036711A 2015-05-22 2016-05-23 항-Pre-S1 HBV 항체 Active KR102770671B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015079534 2015-05-22
CNPCT/CN2015/079534 2015-05-22
PCT/CN2016/082985 WO2016188386A1 (en) 2015-05-22 2016-05-23 Anti-Pre-S1 HBV Antibodies

Publications (2)

Publication Number Publication Date
KR20180009780A KR20180009780A (ko) 2018-01-29
KR102770671B1 true KR102770671B1 (ko) 2025-02-24

Family

ID=57392535

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177036711A Active KR102770671B1 (ko) 2015-05-22 2016-05-23 항-Pre-S1 HBV 항체

Country Status (10)

Country Link
US (3) US20180094047A1 (cg-RX-API-DMAC7.html)
EP (2) EP3978521A1 (cg-RX-API-DMAC7.html)
JP (2) JP6820278B2 (cg-RX-API-DMAC7.html)
KR (1) KR102770671B1 (cg-RX-API-DMAC7.html)
CN (3) CN113527470B (cg-RX-API-DMAC7.html)
ES (1) ES2896275T3 (cg-RX-API-DMAC7.html)
HK (1) HK1243429A1 (cg-RX-API-DMAC7.html)
MA (1) MA42137A (cg-RX-API-DMAC7.html)
RU (1) RU2739955C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016188386A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102770671B1 (ko) 2015-05-22 2025-02-24 화후이 헬스 리미티드 항-Pre-S1 HBV 항체
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
JP7454855B2 (ja) * 2018-12-21 2024-03-25 国立大学法人広島大学 抗ｐｒｅＳ１抗体およびその用途
WO2021013135A1 (en) * 2019-07-20 2021-01-28 Huahui Health Ltd. A method of treating hbv infection by using anti-pre-s1 hbv antibodies
JP2024525184A (ja) * 2021-06-15 2024-07-10 アピットバイオ， インク． Ｂ型肝炎ウイルスｐｒｅＳ１抗原の肝細胞受容体結合部位に特異的に結合するヒト抗体及びその用途
WO2023039243A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
CN116568808A (zh) * 2021-10-19 2023-08-08 北京三诺佳邑生物技术有限责任公司 特异性结合乙型肝炎病毒表面抗原pre-S1的抗体及其应用
CN114685663B (zh) * 2022-04-07 2023-09-08 西南大学 一种抗胆固醇依赖性细胞溶素的抗体及其应用
CN117304308A (zh) * 2022-06-20 2023-12-29 华辉安健（北京）生物科技有限公司 抗乙型肝炎病毒的抗体及其制备和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070116721A1 (en) 2001-07-27 2007-05-24 Philippe Gripon Hepatitis B virus pre-S1 derived synthetic polypeptides and uses thereof
WO2013159243A1 (en) 2012-04-25 2013-10-31 National Institute Of Biological Sciences, Beijing Compositions and uses of functional receptor for hbv/hdv virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
CA2041772A1 (en) * 1990-05-11 1991-11-12 Larry T. Mimms Monoclonal antibodies to pres2 and pres1 polypeptide of the hepatitis b viral envelope
ATE207119T1 (de) * 1992-11-06 2001-11-15 Sandoz Ltd Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
KR100345463B1 (ko) 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
CN1216914C (zh) * 2000-05-17 2005-08-31 韩国科学技术研究院 对hbv表面抗原pre－s1具有特异性的人源化抗体
KR100423614B1 (ko) * 2001-05-16 2004-03-22 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CN1733798B (zh) * 2005-08-12 2012-07-04 上海贺普生物科技有限公司 乙型肝炎病毒表面l蛋白相关肽
WO2011045079A1 (en) * 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
KR102770671B1 (ko) 2015-05-22 2025-02-24 화후이 헬스 리미티드 항-Pre-S1 HBV 항체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070116721A1 (en) 2001-07-27 2007-05-24 Philippe Gripon Hepatitis B virus pre-S1 derived synthetic polypeptides and uses thereof
WO2013159243A1 (en) 2012-04-25 2013-10-31 National Institute Of Biological Sciences, Beijing Compositions and uses of functional receptor for hbv/hdv virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
공개특허공보 제10-2000-33008호*

Also Published As

Publication number Publication date
US10544205B2 (en) 2020-01-28
JP2020171311A (ja) 2020-10-22
JP6820278B2 (ja) 2021-01-27
CN107614525A (zh) 2018-01-19
CN117247944A (zh) 2023-12-19
EP3298038A4 (en) 2019-04-24
WO2016188386A1 (en) 2016-12-01
EP3978521A1 (en) 2022-04-06
CN113527470A (zh) 2021-10-22
US20180148496A1 (en) 2018-05-31
CN113527470B (zh) 2023-08-25
US11485774B2 (en) 2022-11-01
RU2017145085A3 (cg-RX-API-DMAC7.html) 2020-01-23
EP3298038B1 (en) 2021-08-04
MA42137A (fr) 2021-04-07
EP3298038A1 (en) 2018-03-28
US20180094047A1 (en) 2018-04-05
ES2896275T3 (es) 2022-02-24
RU2739955C2 (ru) 2020-12-30
KR20180009780A (ko) 2018-01-29
JP7304320B2 (ja) 2023-07-06
US20220275060A9 (en) 2022-09-01
JP2018519804A (ja) 2018-07-26
CN107614525B (zh) 2021-07-06
HK1243429A1 (zh) 2018-07-13
US20200109186A1 (en) 2020-04-09
RU2017145085A (ru) 2019-06-24

Similar Documents

Publication Publication Date Title
KR102770671B1 (ko) 항-Pre-S1 HBV 항체
US12054538B2 (en) Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
KR20210113936A (ko) 항-코로나바이러스 항체 및 사용 방법
TW202216757A (zh) 中和性抗ｓａｒｓ－ｃｏｖ－２抗體及其使用方法
KR101072895B1 (ko) Ｂ형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체
KR102654105B1 (ko) 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
JP2014526886A (ja) マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
CN114685653A (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
KR20220087457A (ko) Lif에 특이적인 결합 분자 및 이의 용도
AU2020280543A1 (en) Anti-hepatitis B virus antibodies and use thereof
TWI904172B (zh) 抗hbv抗體及使用方法
RU2804490C2 (ru) Новые композиции антител для иммунотерапии рака
CN116406375A (zh) 抗SARS-CoV-2刺突蛋白的三聚体抗体
RU2774158C2 (ru) Антитела, направленные против fc-рецептор-подобного белка 5, и способы их применения
TW202204396A (zh) 抗hbv抗體及使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210428

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230320

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240522

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250112

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250217

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250218

End annual number: 3

Start annual number: 1

PG1601 Publication of registration